At its new site, Diagnovus will develop diagnostic tests and offer information about rare forms of cancer, including pediatric cancers to physicians, payers, patients and families.
The new company will also detect, in-license, develop and commercialize diagnostic assays that have been developed at institutions around the US.
Limestone Fund principal Joe Cook said they believe Diagnovus can focus on providing better individualized information to physicians, patients and caregivers in less frequent cancers.